World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
34408
World Ranking
14896
National Ranking
7531

Overview

Kenneth Marek is affiliated with the Institute for Neurodegenerative Disorders in the United States. Their research focuses primarily on medicine with a specialized emphasis on neurology. Among their subfields of study are physiology, radiology, nuclear medicine and imaging, cellular and molecular neuroscience, and cognitive neuroscience.

The scientist's work centers around key topics such as Parkinson's disease mechanisms and treatments, neurological disorders and treatments in general, Alzheimer's disease research and treatments, autism spectrum disorder research, olfactory and sensory function studies, nuclear receptors and signaling, and traumatic brain injury research.

Kenneth Marek has contributed to several peer-reviewed papers, including:

  • "Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study" (2023), published in The Lancet Neurology
  • "A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research" (2024), published in The Lancet Neurology
  • "Trial of Prasinezumab in Early-Stage Parkinson's Disease" (2022), published in New England Journal of Medicine
  • "Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy" (2020), published in JAMA Neurology
  • "Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression" (2020), published in Movement Disorders

Frequent co-authors include:

  • Andrew Siderowf
  • Tanya Simuni
  • Lana M. Chahine
  • Michael C. Brumm
  • Brit Mollenhauer

Kenneth Marek's research has been published in a range of venues, with a particularly strong presence in:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Neurology
  • Journal of Parkinson's Disease
  • npj Parkinson's Disease
  • Alzheimer's & Dementia

Best Publications

  • MDS clinical diagnostic criteria for Parkinson's disease

    Ronald B. Postuma;Daniela Berg;Matthew Stern;Werner Poewe

  • Levodopa and the progression of Parkinson's disease.

    Fahn S;Oakes D;Shoulson I;Kieburtz K

  • The Parkinson Progression Marker Initiative (PPMI)

    Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  • MDS research criteria for prodromal Parkinson's disease

    Daniela Berg;Ronald B. Postuma;Charles H. Adler;Bastiaan R. Bloem

  • Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial

    R. Holloway;I. Shoulson;K. Kieburtz;M. McDermott

  • Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

    J.A. Obeso;M. Stamelou;M. Stamelou;C.G. Goetz;W. Poewe

  • A controlled trial of rasagiline in early Parkinson disease: The tempo study

    Andrew Siderowf;Matthew Stern;Ira Shoulson;Karl Kieburtz

  • Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

    Robert G Holloway;Ira Shoulson;Stanley Fahn;Karl Kieburtz

  • The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort

    Kenneth Marek;Sohini Chowdhury;Andrew Siderowf;Shirley Lasch

  • Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with parkinson’s disease

    Dennis D. Spencer;Dennis D. Spencer;Richard J. Robbins;Frederick Naftolin;Frederick Naftolin;Kenneth L. Marek;Kenneth L. Marek

  • Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis

    H. D. Rosas;W. J. Koroshetz;Y. I. Chen;C. Skeuse

  • Looking backward to move forward: early detection of neurodegenerative disorders.

    Steven T. DeKosky;Kenneth Marek

  • Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease

    Daniela Berg;Ronald B. Postuma;Bastiaan Bloem;Piu Chan

  • [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

    K. L. Marek;J. P. Seibyl;S. S. Zoghbi;Y. Zea-Ponce

  • [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression

    K. Marek;R. Innis;C. van Dyck;B. Fussell

  • Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease

    Ju-Hee Kang;Ju-Hee Kang;David J. Irwin;Alice S. Chen-Plotkin;Andrew Siderowf

  • The role of radiotracer imaging in Parkinson disease

    B. Ravina;D. Eidelberg;J. E. Ahlskog;R. L. Albin

  • Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease

    Michael A. Schwarzschild;Steven R. Schwid;Kenneth Marek;Arthur Watts

  • The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study

    Alexandra Gaenslen;Barbara Unmuth;Jana Godau;Inga Liepelt

  • Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease

    Tatiana Foroud;S. K. Uniacke;L. Liu;Nathan D Pankratz

Frequent Co-Authors

John Seibyl
John Seibyl Yale University
Danna Jennings
Danna Jennings Denali Therapeutics (United States)
Gilles Tamagnan
Gilles Tamagnan Yale University
Caroline M. Tanner
Caroline M. Tanner University of California, San Francisco
Karl Kieburtz
Karl Kieburtz University of Rochester Medical Center
Andrew Siderowf
Andrew Siderowf University of Pennsylvania
Anthony E. Lang
Anthony E. Lang University of Toronto
Robert A. Hauser
Robert A. Hauser University of South Florida
Brit Mollenhauer
Brit Mollenhauer University of Göttingen
Matthew B. Stern
Matthew B. Stern University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in studying Medicine in the USA but seeking flexible alternatives, there are many related online degrees available. Online nursing programs have become particularly popular for students looking to balance studies with work or other commitments. Accredited nursing school online options offer convenience and often greater affordability compared to traditional in-person programs.

For those already holding a registered nurse license, pursuing a bachelor's degree is a natural next step. The cheapest online rn to bsn programs can help you advance your career and open the door to higher-level roles in healthcare.

Aspiring advanced practice nurses might consider enrolling in the cheapest nurse practitioner programs available online. These programs often lead to rewarding, high-demand careers in a variety of healthcare settings.

For those looking toward academic or research-centered roles, a phd in nursing provides the credentials needed for university teaching, policy leadership, or advanced clinical research.

Best Scientists Citing Kenneth Marek

Trending Scientists